Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers

Two drugs developed by Disc Medicine (IRON) and Sanofi (SNY) are facing delays in their review timelines due to safety and ...
Stocktwits on MSN

Disc Medicine, Sanofi, Eli Lilly shares slip on reports of FDA increasing review time for drugs granted priority review vouchers

FDA is slated to decide on Disc Medicine's Bitopertin by February. ・Approval for Lilly’s obesity pill is expected by April 10. ・The FDA has also stalled the review of Sanofi’s Tzield for late-stage ...

Disc Medicine (IRON) Valuation Check As Bitopertin Wins Priority FDA Review And Commercial Plans Advance

Disc Medicine (IRON) has drawn fresh attention after securing priority FDA review for bitopertin and outlining commercialization plans, while also advancing DISC-0974 and DISC-3405 through ongoing ...
TMCnet

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Investing

Disc Medicine stock rating reiterated by Morgan Stanley amid FDA review

Investing.com - Morgan Stanley has reiterated an Overweight rating and $120.00 price target on Disc Medicine (NASDAQ:IRON) following reports about potential FDA review extensions for CNPV drugs. This ...